<PAGE>
[LOGO]
May 10, 1996
Dear Stockholder:
Please be advised that PCA is holding its Annual Stockholders' Meeting on
Friday, June 28, 1996 at 5:00 p.m. ("EDT") at the Hotel Sofitel, 5800 Blue
Lagoon Drive, Miami, Florida.
In connection therewith, enclosed please find the following:
- Annual Report to Stockholders and Form 10-K
- Proxy Statement
- Proxy Card
- Self-addressed, postage paid envelope for your convenience in returning
the Proxy Card
Please complete the enclosed Proxy Card and mail to the transfer agent,
Boatmen's Trust Company, in the enclosed envelope prior to June 28, 1996. We
look forward to seeing you at the Annual Stockholders' Meeting.
Respectfully,
John A. Hageman
Secretary
- - --------------------------------------------------------------------------------
5835 BLUE LAGOON DRIVE, MIAMI, FLORIDA 33126 (305) 267-6633 OR 800-562-9262
FAX NUMBER (305) 265-2939
<PAGE>
PHYSICIAN CORPORATION OF AMERICA
5835 BLUE LAGOON DRIVE
MIAMI, FLORIDA 33126
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD JUNE 28, 1996
The Annual Meeting of the Stockholders of Physician Corporation of America
(the "Company") will be held at the Hotel Sofitel, 5800 Blue Lagoon Drive,
Miami, Florida on the 28th day of June 1996 at 5:00 p.m. for the purpose of
considering and acting upon the following matters:
1. To elect two directors to hold office for the ensuing term and until
their successors are elected and qualified.
2. To approve the selection of KPMG Peat Marwick LLP as independent
auditors for the Company during the 1996 fiscal year.
3. To transact such other business as may properly come before the meeting
or any adjournment.
The stock transfer books of the Company will not be closed, but only
stockholders of record at the close of business on May 6, 1996 will be entitled
to notice of and to vote at the meeting.
By Order of the Board of Directors
John A. Hageman, Secretary
Miami, Florida
May 6, 1996
You are cordially invited to come early so that you may meet informally with
management and Board nominees. The meeting room will be open from 4:00 p.m.
until the meeting time at 5:00 p.m. Refreshments will be served before the
meeting.
IMPORTANT
IF YOU DO NOT EXPECT TO ATTEND THE MEETING, PLEASE SIGN, DATE AND MAIL THE
ENCLOSED PROXY IN THE ENVELOPE PROVIDED, WHICH REQUIRES NO POSTAGE IF MAILED IN
THE UNITED STATES. IT IS IMPORTANT THAT THE PROXY BE RETURNED REGARDLESS OF THE
NUMBER OF SHARES OWNED.
<PAGE>
PHYSICIAN CORPORATION OF AMERICA
5835 BLUE LAGOON DRIVE
MIAMI, FLORIDA 33126
------------------------
THE APPROXIMATE MAILING DATE OF THIS PROXY STATEMENT IS MAY 10, 1996
------------------------
PROXY STATEMENT
FOR ANNUAL MEETING OF STOCKHOLDERS
JUNE 28, 1996
---------------------
The accompanying proxy is furnished by Physician Corporation of America (the
"Company") in connection with the solicitation by the Board of Directors and may
be revoked by the stockholder at any time before it is voted by giving a written
notice to the Secretary of the Company, by executing and delivering a proxy with
a later date, or by personal withdrawal of the proxy prior to or at the meeting.
The expense of this solicitation is to be borne by the Company and the Company
will reimburse persons holding stock in their name or in the names of their
nominees, for their expenses in sending proxies and proxy materials to their
principals.
The Company had issued and outstanding 38,705,685 shares of Common Stock,
par value $0.01 per share, as of May 6, 1996, the date the stockholders of
record entitled to vote at the meeting was determined (the "Record Date"). Each
stockholder as of the Record Date will be entitled to one vote per share on all
matters acted upon at the Annual Meeting. Neither the Certificate of
Incorporation nor the Bylaws of the Company provide for cumulative voting
rights.
PRINCIPAL HOLDERS OF SECURITIES
The following table sets forth certain information with regard to the
beneficial ownership of Common Stock as of January 1, 1996 by (i) each
stockholder who is known by the Company to beneficially own in excess of 5% of
the outstanding shares of Common Stock, (ii) each director, (iii) each of the
executive officers named in the Summary Compensation Table, and (iv) all
directors and executive officers as a group. Except as otherwise indicated, each
stockholder listed below has sole voting and investment power with respect to
shares beneficially owned by such person.
<TABLE>
<CAPTION>
AMOUNT AND
NATURE OF PERCENT OF
NAME AND ADDRESS (1) BENEFICIAL OWNERSHIP CLASS
- - --------------------------------------------------------------------- -------------------- -------------
<S> <C> <C>
E. Stanley Kardatzke, M.D.(2) 3,146,533 8.1%
Peter E. Kilissanly(3) 850,398 2.2%
Clifford W. Donnelly(4) 266,800 *
Glen R. Johnson, M.D.(5) 96,600 *
Donald J. Gessler, M.D.(6) 126,000 *
George J. Farha, M.D.(7) 644,332 1.7%
William C. Loewen, M.D.(8) 577,332 1.5%
Clark R. Mandigo(9) 271,664 *
All directors and executive officers as a group 6,227,963 15.9%
(9 individuals)(10)
</TABLE>
- - ------------------------
* Less than 1%
(1) The business address of all officers and directors of the Company is 5835
Blue Lagoon Drive, Miami, Florida 33126.
<PAGE>
(2) Includes (i) 182,482 shares held in trust as to which Dr. Kardatzke's wife
has sole voting and investment power, (ii) 292,750 shares held by a
charitable foundation of which Dr. Kardatzke holds voting and investment
power, and (iii) 84,000 shares subject to stock options which are fully
vested and exercisable.
(3) Includes (i) 173,332 shares held in trust as to which Mr. Kilissanly holds
sole voting and investment power, (ii) 800 shares owned by Mr. Kilissanly's
wife who has sole voting and investment power with respect to such shares,
and (iii) 56,000 shares subject to stock options which are fully vested and
exercisable.
(4) Includes (i) 20,000 shares owned by Mr. Donnelly's wife who has sole voting
and investment power with respect to such shares, and (ii) 46,800 shares
subject to stock options which are fully vested and exercisable.
(5) Includes (i) 2,666 shares owned by Dr. Johnson's wife who has sole voting
and investment power with respect to such shares, (ii) 15,200 shares held in
an Individual Retirement Account for the benefit of Dr. Johnson, (iii) 400
shares held in an Individual Retirement Account for the benefit of Dr.
Johnson's wife, and (iv) 22,000 shares subject to stock options which are
fully vested and exercisable.
(6) Includes 106,000 shares subject to stock options, which are fully vested
and exercisable.
(7) Includes 6,000 shares subject to stock options which are fully vested and
exercisable.
(8) Includes (i) 100,000 shares owned by Dr. Loewen's wife who has sole voting
and investment power with respect to such shares, (ii) 50,000 shares held by
a charitable foundation of which Dr. Loewen shares voting and investment
power, and (iii) 12,000 shares subject to stock options which are fully
vested and exercisable.
(9) Includes (i) 22,664 shares held in trusts for the benefit of Mr. Mandigo's
children, (ii) 93,334 shares owned jointly with Mr. Mandigo's wife, (iii)
11,666 shares held in an Individual Retirement Account for the benefit of
Mr. Mandigo, and (iv) 52,000 shares subject to stock options which are fully
vested and exercisable.
(10) Includes 483,600 shares subject to stock options which are fully vested and
exercisable.
ELECTION OF DIRECTORS
The Company's Certificate of Incorporation divides the Board of Directors
into three classes of as equal size as possible, with the term of each class
expiring in consecutive years so that only one class is elected in any given
year. Successors to those whose terms have expired are required to be elected by
stockholder vote. Vacancies in unexpired terms and any additional positions
created by Board action are filled by action of the existing Board of Directors.
The terms of office of Drs. Kardatzke and Farha will expire at the 1996 Annual
Meeting of Stockholders, the terms of office of Messrs. Kilissanly and Mandigo
will expire at the 1997 Annual Meeting of Stockholders and the term of office of
Dr. Loewen will expire at the 1998 Annual Meeting of Stockholders.
The following nominees of the Company for the Board of Directors are all
currently serving on the Board with terms expiring at the 1996 Annual Meeting of
Stockholders. All have been nominated for reelection to the Board to serve until
the Annual Meeting of Stockholders in 1999.
2
<PAGE>
NOMINEES FOR ELECTION OF DIRECTORS
<TABLE>
<CAPTION>
YEAR BECAME
NAME POSITION(S) AGE DIRECTOR
- - ------------------------------- --------------------------------------- --- ------------
<S> <C> <C> <C>
E. Stanley Kardatzke, M.D. Chairman of the Board, Chief Executive 57 1985
Officer and Director
George J. Farha, M.D. Vice Chairman of the Board and Director 68 1986
</TABLE>
E. STANLEY KARDATZKE, M.D. has been Chairman of the Board and Chief
Executive Officer of the Company since 1985, when he founded the Company. Dr.
Kardatzke was Chairman of the Board of Health Care Plus of America, Inc., an HMO
operating in the Wichita, Kansas area ("Health Care Plus") from 1983 through
1985, and was the medical director of Health Care Plus from 1980 to 1983. Before
becoming associated with Health Care Plus, Dr. Kardatzke was, for 18 years, a
family practice physician in private practice in Wichita, Kansas.
GEORGE J. FARHA, M.D. has been a Director of the Company since 1986, and
Vice Chairman of the Board of the Company since 1989, and served as the
Company's President from 1986 to 1989. For the past 30 years, Dr. Farha has been
a practicing general surgeon and President and Chief Executive Officer of the
Wichita Surgical Specialists, P.A. and its predecessor Wichita Surgical Group,
P.A. He also is, and for the past 18 years has been, a professor and Chairman of
the Department of Surgery at the University of Kansas School of Medicine in
Wichita, Kansas.
THE BOARD HAS UNANIMOUSLY APPROVED THE ABOVE-NAMED NOMINEES FOR DIRECTOR AND
RECOMMENDS A VOTE "FOR" THEIR ELECTION.
DIRECTORS WHOSE TERMS
EXPIRE IN 1997
<TABLE>
<CAPTION>
YEAR BECAME
NAME POSITION(S) AGE DIRECTOR
- - ------------------------------- --------------------------------------- --- ------------
<S> <C> <C> <C>
Peter E. Kilissanly President, Chief Operating Officer and 48 1986
Director
Clark R. Mandigo Director 52 1986
</TABLE>
PETER E. KILISSANLY has been President of the Company since 1989, Chief
Operating Officer and a Director of the Company since 1986, and is President and
Chief Executive Officer of PCA Health Plans of Florida, Inc. ("PCA/Florida") and
PCA Solutions, Inc. and President and Chief Executive Officer of Century Medical
Health Plans, Inc., ("Century"). Mr. Kilissanly served as Vice Chairman of the
Board of the Company from 1986 to 1989. Mr. Kilissanly was the Senior Vice
President of Marketing of Health Care Plus from 1981 to 1986.
CLARK R. MANDIGO has been a Director of the Company since 1986. Mr. Mandigo
has been a business consultant since 1991. Mr. Mandigo was the President and
Chief Executive Officer of Intelogic Trace, Inc., a corporation engaged in the
sale, lease and support of computer and communications systems and equipment
from 1986 to 1991. Mr. Mandigo is a member of the Board of Directors of Lone
Star Steakhouse and Saloon, Inc., a restaurant chain, Palmer Wireless, Inc., a
cellular telephone system operator and Trustee of Accolade Funds and
Pauze/Swanson United Services Funds.
DIRECTOR WHOSE TERM
EXPIRES IN 1998
<TABLE>
<CAPTION>
YEAR BECAME
NAME POSITION AGE DIRECTOR
- - ------------------------------- --------------------------------------- --- ------------
<S> <C> <C> <C>
William C. Loewen, M.D. Director 54 1986
</TABLE>
3
<PAGE>
WILLIAM C. LOEWEN, M.D. has been a Director of the Company since 1986. Dr.
Loewen served as Senior Vice President of Medical Affairs of the Company from
1986 to 1989. For the past 23 years, Dr. Loewen has been a practicing family
physician in Wichita, Kansas. He is a member of the American Academy of Family
Physicians, of which he is both board certified and an elected Fellow. He is the
past Chief of Medical Staff of St. Francis Regional Medical Center, Inc.,
Wichita, Kansas.
ATTENDANCE AT BOARD MEETINGS
During the fiscal year ended December 31, 1995, the Board of Directors held
a total of twelve regular and telephonic meetings. All directors attended or
participated in at least 75% of the Board Meetings.
COMMITTEES OF THE BOARD OF DIRECTORS
The Board of Directors has established an Audit Committee, of which Drs.
Farha and Loewen and Mr. Mandigo are members, a Compensation Committee, of which
Drs. Farha and Loewen and Mr. Mandigo are members and a Stock Option Committee
of which Dr. Farha and Mr. Mandigo are members. The functions of the Audit
Committee are to recommend annually to the Board of Directors the appointment of
the independent public accountants of the Company, discuss and review the scope
and the fees of the prospective annual audit and review the results thereof with
the independent public accountants, review and approve non-audit services of the
independent public accountants, review compliance with existing major accounting
and financial policies of the Company, review the adequacy of the financial
organization of the Company and review management's procedures and policies
relative to the adequacy of the Company's internal accounting controls and
compliance with federal and state laws relating to accounting practices. The
Audit Committee met three times during the fiscal year ended December 31, 1995.
All committee members attended these committee meetings.
The functions of the Compensation Committee, as delegated by the Board of
Directors, are to review and approve annual salaries and bonuses for all
executive officers and review and approve the terms and conditions of all
employee benefit plans or changes thereto. The Compensation Committee met two
times during the fiscal year ended December 31, 1995. All committee members
attended these committee meetings.
The functions of the Stock Option Committee, as delegated by the Board of
Directors, are to administer and interpret the terms and conditions of the
Company's stock option plans and to review and approve grants of stock options
pursuant to the Company's stock option plans for all executive officers of the
Company. The Stock Option Committee met three times during the fiscal year ended
December 31, 1995. All committee members attended these meetings.
4
<PAGE>
EXECUTIVE OFFICERS
The officers of the Company are elected at the Board of Directors' annual
organizational meeting immediately following the Annual Stockholders' Meeting.
Such officers hold office until their successors are chosen and qualified or
until their death, resignation or removal. The names of the executive officers
of the Company and significant employees of the Company's HMOs, and their
respective ages and positions are as follows:
<TABLE>
<CAPTION>
NAME AGE POSITION
- - ------------------------------- --- -----------------------------------------------------------------
<S> <C> <C>
E. Stanley Kardatzke, M.D. 57 Chairman of the Board and Chief Executive Officer
Peter E. Kilissanly 48 President, Chief Operating Officer and Director
Clifford W. Donnelly 42 Senior Vice President of Finance and Chief Financial Officer
Glen R. Johnson, M.D. 53 Senior Vice President of Medical Affairs
John A. Hageman 41 Senior Vice President of Legal Affairs, General Counsel and
Secretary
Donald J. Gessler, M.D. 54 President and Chief Executive Officer of PCA Health Plans of
Texas, Inc.
</TABLE>
E. STANLEY KARDATZKE, M.D. has been Chairman of the Board and Chief
Executive Officer of the Company since 1985, when he founded the Company. Dr.
Kardatzke was Chairman of the Board of Health Care Plus, from 1983 through 1985,
and was the medical director of Health Care Plus from 1980 to 1983. Before
becoming associated with Health Care Plus, Dr. Kardatzke was, for 18 years, a
family practice physician in private practice in Wichita, Kansas.
PETER E. KILISSANLY has been President of the Company since 1989, Chief
Operating Officer and a Director of the Company since 1986, President and Chief
Executive Officer of PCA/Florida and PCA Solutions, Inc. and President and Chief
Executive Officer of Century. Mr. Kilissanly was the Senior Vice President of
Marketing of Health Care Plus from 1981 to 1986.
CLIFFORD W. DONNELLY has been Senior Vice President of Finance and Chief
Financial Officer of the Company since 1988, and the President of PCA Life
Insurance Company since 1990. Mr. Donnelly was Chief Financial Officer for
American City Business Journals, a chain of weekly business journals, from 1982
to 1988. From 1977 to 1982, Mr. Donnelly was an audit manager for Fox & Company,
a public accounting firm. Mr. Donnelly is a certified public accountant.
GLEN R. JOHNSON, M.D. has been Senior Vice President of Medical Affairs of
the Company since 1990. Dr. Johnson was Vice President of Medical Affairs of PCA
Health Plans of Texas, Inc. ("PCA/Texas") from 1989 to June 1992. Dr. Johnson
was a family practice physician in private practice from 1975 to 1989 and was
director of the family practice residency program of Central Texas Medical
Foundation from 1977 to 1987. Dr. Johnson is currently Vice President and a
director of the American Academy of Family Physicians and serves on its
executive committee.
JOHN A. HAGEMAN has been General Counsel and Secretary of the Company since
1987 and Senior Vice President of Legal Affairs since 1994. Prior to joining the
Company in 1987, Mr. Hageman was a partner in a Wichita, Kansas law firm and had
been associated with such firm since 1981. Mr. Hageman is a member of the
American and Kansas Bar Associations and the National Health Lawyers
Association.
DONALD J. GESSLER, M.D. has been President and Chief Executive Officer of
PCA/Texas since 1990. Dr. Gessler was Executive Vice President of PCA/Texas from
1987 through 1989. Dr. Gessler was Vice President and General Manager of Cigna
Health Plan in Houston, Texas from 1983 to 1987. Dr. Gessler was program
director of family practice residency for St. Francis Regional Medical Center,
Inc., located in Wichita, Kansas, from 1975 to 1983.
5
<PAGE>
EXECUTIVE COMPENSATION
The following table sets forth the cash compensation paid or accrued during
the fiscal years ended December 31, 1993, 1994 and 1995, to the Company's Chief
Executive Officer and the five highest paid executive officers of the Company
whose annual cash compensation exceeds $100,000.
SUMMARY COMPENSATION TABLE
<TABLE>
<CAPTION>
LONG TERM
COMPENSATION
AWARDS
ANNUAL COMPENSATION -----------------
---------------------------------------------------- SECURITIES
OTHER ANNUAL UNDERLYING ALL OTHER
NAME AND PRINCIPAL POSITION YEAR SALARY BONUS (1) COMPENSATION (2) OPTIONS/SARS (#) COMPENSATION (3)
- - ----------------------------------- --------- ---------- ---------- ----------------- ----------------- -----------------
<S> <C> <C> <C> <C> <C> <C>
E. Stanley Kardatzke, M.D. 1995 $ 336,210 $ -- $ 8,418 -- $ 2,878
Chairman of the Board and Chief 1994 341,940 82,167 9,129 -- 4,620
Executive Officer 1993 316,614 475,021 23,242 140,000 4,497
Peter E. Kilissanly 1995 352,993 -- 6,133 -- 2,188
President and Chief Operating 1994 326,402 78,437 6,421 -- 4,620
Officer 1993 302,224 453,436 18,352 140,000 4,497
Clifford W. Donnelly 1995 225,000 -- 5,277 -- 4,620
Senior Vice President of Finance 1994 208,275 29,992 5,390 -- 4,620
and Chief Financial Officer 1993 192,847 173,662 5,485 110,000 4,497
Glen R. Johnson, M.D. 1995 272,544 -- 6,465 -- 4,620
Senior Vice President of Medical 1994 259,565 37,478 6,864 -- 4,620
Affairs 1993 240,339 216,405 18,814 110,000 4,497
Donald J. Gessler, M.D. 1995 210,000 -- 6,870 -- 4,620
President and Chief Executive 1994 183,803 20,658 6,655 -- 4,620
Officer of 1993 165,850 32,793 5,176 110,000 4,497
PCA/Texas
Neil A. Natkow, D.O. (4) 1995 132,636 -- 59 -- 4,620
President and Chief Operating 1994 228,269 20,788 1,178 -- 484,621 (5)
Officer of PCA/ Family 1993 $ 19,231 $ -- $ 17,471 50,000 $ 50,000
</TABLE>
- - ------------------------
(1) Amounts represent discretionary cash bonuses paid and accrued pursuant to
then existing Company incentive bonus plans.
(2) Represents payments for unused vacation time, relocation allowances, group
term life insurance, and automobile allowances.
(3) Represents contributions made by the Company under the Physician Corporation
of America 401(k) Profit Sharing Plan.
(4) Dr. Natkow resigned in September 1995 for health reasons.
(5) Includes payments in the aggregate amount of $200,000 made pursuant to a
covenant not to compete which was entered into as a result of the Family
Health acquisition and $278,998 resulting from payment of termination of an
employment agreement.
Effective January 1, 1996, the Company entered into change of control
agreements with the executives named above (with exception of Dr. Natkow). These
agreements provide for the payment of a severance benefit upon a change in
control of the Company should the employee be terminated or demoted without good
cause. The severance benefits include a payment of up to 18 months of salary,
the
6
<PAGE>
continuation of eligibility for participation in the Company's benefit programs
and the immediate vesting of all unvested stock options at the employee's
termination date. The benefits are ratably decreased as time elapses after a
change in control and expires no later than 18 months after a change of control.
OPTION GRANTS IN FISCAL YEAR 1995
During the fiscal year ended December 31, 1995, the Company did not grant
stock options to any executive officers named in the Summary Compensation Table.
AGGREGATED OPTION EXERCISES IN FISCAL YEAR 1995
The following table sets forth information with respect to stock options
exercised by the Company's Chief Executive Officer and the five highest paid
executive officers of the Company in fiscal year 1995 and unexercised options
held as of December 31, 1995.
AGGREGATED OPTION EXERCISES IN LAST FISCAL YEAR
AND FISCAL YEAR-END OPTION VALUES
<TABLE>
<CAPTION>
NUMBER OF SECURITIES
UNDERLYING VALUE OF UNEXERCISED
UNEXERCISED OPTIONS IN-THE-MONEY OPTIONS
AT DECEMBER 31, 1995 AT DECEMBER 31, 1995
-------------------- -----------------------
SHARES ACQUIRED VALUE EXERCISABLE/ EXERCISABLE/
NAME ON EXERCISE REALIZED (1) UNEXERCISABLE UNEXERCISABLE (2)
- - ---------------------------------- ---------------- ------------ -------------------- -----------------------
<S> <C> <C> <C> <C>
E. Stanley Kardatzke, M.D. -- $ -- 84,000/56,000 $ 1,428,000/$952,000
Chairman of the Board and Chief
Executive Officer
Peter E. Kilissanly -- -- 56,000/56,000 952,000/952,000
President and Chief Operating
Officer
Clifford W. Donnelly 112,200 2,136,075 46,800/44,000 795,600/748,000
Senior Vice President of Finance
and Chief Financial Officer
Glen R. Johnson, M.D. 22,000 299,750 22,000/44,000 374,000/748,000
Senior Vice President of Medical
Affairs
Donald J. Gessler, M.D. -- -- 106,000/44,000 1,802,000/748,000
President and Chief Executive
Officer of PCA/ Texas
Neil A. Natkow, D.O. -- $ -- -- /-- $ -- /$ --
President and Chief Operating
Officer of PCA/ Family
</TABLE>
- - ------------------------
(1) Value realized is the difference between the market price of the underlying
common stock on the exercise date and the exercise price.
(2) Values have been computed based on the last reported sale price on December
29, 1995 of $17.00 per share.
7
<PAGE>
STOCK PERFORMANCE GRAPH
The following graph shows an indexed comparison of the cumulative total
return on the Company's Common Stock, the Standard & Poor's 500 Index and a
self-constructed peer group index [consisting of FHP International, Inc., (from
April 1994 when it acquired Takecare, Inc.) Foundation Health Corporation,
Healthsource, Inc., Health Systems International, Inc. (from February 1994 when
it acquired Qual Med, Inc.), Humana, Inc., Oxford Health Plans, Inc., Pacificare
Health Systems, Inc., Physicians Health Services, Inc., Qual Med, Inc. (until
December 1993 when it was acquired by Health Systems International, Inc.),
Ramsay-HMO, Inc. (until March 1994 when it was acquired by United Health Care
Corporation), Sierra Health Services, Inc., Takecare, Inc. (until March 1994
when it was acquired by FHP International, Inc.) and United Health Care
Corporation (from April 1994 when it acquired Ramsay-HMO, Inc.)] commencing with
the listing of the Company's Common Stock on the Nasdaq National Market on March
30, 1993. This graph assumes that $100 was invested on March 30, 1993 in Company
Common Stock and in each company in each index as of March 30, 1993 and that all
dividends were reinvested.
EDGAR REPRESENTATION OF DATA POINTS USED IN PRINTED GRAPHIC
<TABLE>
<CAPTION>
S&P 500 PEER GROUP PCAM
<S> <C> <C> <C>
3/31/93 $ 100 $ 100 $ 100
4/30/93 97 105 130
5/31/93 100 128 180
6/30/93 100 126 178
7/31/93 99 126 245
8/31/93 103 120 223
9/30/93 102 130 238
10/31/93 104 127 259
11/30/93 102 137 319
12/31/93 103 159 313
1/31/94 107 159 369
2/28/94 103 186 338
3/31/94 99 180 333
4/30/94 100 145 301
5/31/94 101 159 264
6/30/94 98 129 281
7/31/94 101 140 275
8/31/94 105 160 263
9/30/94 102 167 283
10/31/94 105 177 302
11/30/94 100 163 322
12/31/94 102 173 256
1/31/95 104 183 300
2/28/95 108 187 278
3/31/95 111 208 281
4/30/95 114 163 223
5/31/95 118 176 275
6/30/95 121 163 170
7/31/95 124 175 204
8/31/95 124 174 200
9/30/95 129 197 197
10/31/95 129 213 192
11/30/95 134 234 189
12/31/95 $ 136 $ 231 $ 213
</TABLE>
COMPENSATION COMMITTEE REPORT
ON EXECUTIVE COMPENSATION
GENERAL
The Compensation Committee (the "Committee") of the Board of Directors
determines the cash and other incentive compensation (with the exception of
stock options which are granted by the Stock Option Committee), if any, to be
paid to the Company's executive officers. The Committee is comprised of Drs.
Farha and Loewen and Mr. Mandigo and the Stock Option Committee is comprised of
Dr. Farha and Mr. Mandigo. Mr. Mandigo serves as Chairman of the Committee and
of the Stock Option Committee. All members of both Committees are "disinterested
directors" (within the meaning of Rule 16b-3 under the Securities Exchange Act
on 1934).
8
<PAGE>
OBJECTIVE
It is the Committee's objective, working when appropriate in tandem with the
Stock Option Committee, that the compensation of the Company's executive
officers be heavily influenced by the Company's short and long-term performance
and that the financial interests of the executives be aligned closely with those
of the Company's stockholders. To achieve this objective, there are three
components of executive compensation: (i) base salary; (ii) annual incentive
bonus; and (iii) stock options.
SALARIES
Base salaries for executive officers, including the Chief Executive Officer,
are established by considering a number of factors, including the Company's
overall performance, the executive's individual performance and contribution to
the Company's performance, and the salaries of persons holding similar positions
with peer companies in the HMO industry. The Committee believes that the
Company's most direct competitors for executive talent are not confined to the
companies comprising the peer group used in the Stock Performance Graph and
therefore the compensation peer group includes all publicly traded HMOs. The
Committee believes that the salaries of the Company's executives are near the
average of the compensation peer group. Salary data of competitor companies is
furnished by outside consultants or derived from publicly available information.
Evaluation of the individual executive's performance and contribution to the
Company's performance are somewhat subjective. For base salary purposes, the
Company's performance is evaluated by comparing actual financial and operating
results to projected results and the results from the previous year, and
although relative weights are not assigned, the performance measurements
considered most important by the Committee are the Company's net earnings
growth, revenue growth, medical loss ratio and operating margin.
Annually, the Committee reviews the base salary of the Company's executive
officers and considers adjustments to the salary of each. After considering the
factors described above, the Committee makes adjustments as it deems
appropriate.
In 1994, the Company's net earnings improved to $52.5 million from $40.1
million in 1993 and total revenues increased 50%, while HMO medical loss ratio
increased to 73.9% from 72.8% and operating margin declined to 10.8% from 12.3%.
Further, 1994 results were, in general, below internal projections. The
Committee believed that the earnings and revenue increases in 1994 overshadowed
the margin deterioration and forecast shortfall, and awarded the Chief Executive
Officer an increase of 8.0% in his base salary for 1995. After considering the
Company's financial results for the year ended December 31, 1995, the
Compensation Committee has awarded no salary increases to any of the Company's
corporate executives in 1996.
INCENTIVE BONUSES
Under the Company's Incentive Bonus Plan (the "Plan"), the Committee
annually establishes a target award for each participating executive. This
target depends on the Committee's assessment of the executive's ability to
influence the results of the Company and ranges from 35% of base annual
compensation to 100% of base annual compensation. However, the Committee may
reduce the amount of the award to an executive if it determines that he or she
did not perform his or her responsibilities adequately. The 1995 target award
for the Chief Executive Officer was 100% of his base salary.
The percentage of an executive's target award which could be paid for 1995
results was dependent upon achieving a targeted earnings level. The incentive
bonus percentage which could have been awarded ranged from (i) 0% of the target
award if the targeted earnings level was not met; (ii) 20% to 100% of the target
award if the targeted earnings level was partially or fully achieved; and (iii)
an additional amount equal to 6% of the target award for each one cent the
earnings per share exceeded the targeted earnings level. For 1995, no bonuses
were earned under the Plan and none were paid.
STOCK OPTIONS
Stock option grants are designed to strengthen the link between executive
compensation and long-term Company performance. The number of shares granted are
based on the executive's level of responsibility, the length of time since the
last option grant was made to the executive and the executive's
9
<PAGE>
base salary. Options are granted at 100% of fair market value on the date of
grant and have a ten year term. Generally, stock options granted to the
Company's executive officers have a four to five year vesting period.
Any value received by an executive from an option grant depends completely
upon increases in the price of the Company's stock. Consequently, the Committee
believes that stock options are an appropriate method of aligning managements'
and stockholders' interests in the enhancement of stockholder value. No stock
option grants were made to executive officers in 1995.
COMPLIANCE WITH SECTION 162(M) OF THE INTERNAL REVENUE CODE OF 1986
The Company intends to comply with the requirements of Section 162(m) of the
Internal Revenue Code. The Company does not expect cash compensation to be
affected by the requirements of Section 162(m) for fiscal 1995. If required for
future fiscal years, the Company intends to submit to stockholders any matters
required by Section 162(m).
Compensation Committee:
George J. Farha, M.D.
William C. Loewen, M.D.
Clark R. Mandigo
Stock Option Committee:
George J. Farha, M.D.
Clark R. Mandigo
COMPENSATION COMMITTEE INTERLOCKS
AND INSIDER PARTICIPATION
No current officer of the Company serves on either the Compensation or Stock
Option Committee, and there are no "interlocks" as defined by the Securities and
Exchange Commission. Drs. Farha and Loewen who serve on the Compensation
Committee were officers of the Company from 1986 to 1989.
DIRECTORS' COMPENSATION
All Board members, other than employees of the Company (presently, Dr.
Kardatzke and Mr. Kilissanly) receive $2,500 per quarter for their services as
directors, $1,500 for each Board meeting attended, $250 for participation in
each telephonic Board meeting, $500 for each Board committee meeting attended
($1,000 if such Board committee meeting is held on a date when a Board meeting
is not also held), $4,000 annually for serving as a Board committee Chairman
(limited to $4,000 per Board member even if such member serves as Chairman for
more than one Committee), and reimbursement by the Company of out-of-pocket
expenses incurred for attendance at meetings. Pursuant to the 1993 Stock Option
Plan, the Company also grants automatic, nondiscretionary stock options to
purchase 6,000 shares to each of its non-employee directors annually. Such
options have a one year vesting period and an exercise price per share equal to
the fair market value per share on the date of the grant. In addition, each
newly elected non-employee director will receive an automatic, nondiscretionary
grant of stock options to purchase 12,000 shares on the date of his or her
initial election to the Board of Directors of the Company, vesting ratably over
a three year period at an exercise price per share equal to the fair market
value per share on the date of grant.
TRANSACTIONS WITH MANAGEMENT
As a condition to the acquisition of Family Health, the Company entered into
a five-year covenant not-to-compete with Dr. Neil A. Natkow, President and Chief
Executive Officer of PCA/Florida.
10
<PAGE>
Dr. Natkow will receive from the Company an aggregate amount of $1,000,000
payable in 20 quarterly installments of $50,000, which payments commenced on
December 1, 1993 and which will end on September 1, 1998. Dr. Natkow resigned as
an Officer of the Company in September 1995.
The Company believes that the terms of the transaction described above with
Dr. Natkow are no less favorable to the Company than the Company could have
obtained from non-affiliated parties. In the future, all transactions between
the Company and its affiliated entities, executive officers, directors or
stockholders will be on terms which will continue to be no less favorable to the
Company than the Company could obtain from non-affiliated parties.
COMPLIANCE WITH SECTION 16(A)
OF THE SECURITIES EXCHANGE ACT OF 1934
Section 16(a) of the Securities Exchange Act of 1934 requires the Company's
officers and directors, and persons who own more than 10% of a registered class
of the Company's equity securities, to file reports of ownership and changes in
ownership with the Securities and Exchange Commission. Officers, directors and
greater than 10% stockholders are required by the Securities and Exchange
Commission regulation to furnish the Company with copies of all Section 16(a)
forms they file.
Based solely on review of the copies of such forms furnished to the Company,
or written representations that no Form 5s were required, the Company believes
that during the fiscal year ended December 31, 1995, all officers, directors and
greater than 10% beneficial owners complied with all Section 16(a) filing
requirements applicable to such individuals, except for Mr. Donnelly who failed
to timely file a Form 4 reporting the exercise of a stock option and the
subsequent sale of such stock. Mr. Donnelly has filed a Form 5 reporting these
transactions.
ELECTION OF AUDITORS
The stockholders are being asked to approve the selection of KPMG Peat
Marwick LLP, independent certified public accountants, as auditors for the
Company for the fiscal year ending December 31, 1996.
The audit for the Company for the year ended December 31, 1995, was
conducted by KPMG Peat Marwick LLP. A representative of such firm is expected to
be present to answer appropriate questions, but does not intend to make a
statement.
THE BOARD OF DIRECTORS OF THE COMPANY UNANIMOUSLY RECOMMENDS A VOTE "FOR"
THE SELECTION OF KPMG PEAT MARWICK LLP AS AUDITORS FOR THE COMPANY FOR THE 1996
FISCAL YEAR.
VOTE REQUIRED
The two nominees for election as directors at the Annual Meeting of
Stockholders who receive the greatest number of votes cast for the election of
directors at that meeting by the holders of the Company's Common Stock will
become directors at the conclusion of the tabulation of votes. An affirmative
vote of the majority of the total votes cast in person or by proxy at the Annual
Meeting of Stockholders is necessary to elect KPMG Peat Marwick LLP as auditors
for the Company.
Under Delaware Law and the Company's Certificate of Incorporation and
By-laws, the aggregate number of votes entitled to be cast by all stockholders
present in person or represented by proxy at the meeting, whether those
stockholders vote "for", "against" or abstain from voting, will be counted for
purposes of determining the minimum number of affirmative votes required for
approval of the second proposal, and the total number of votes cast "for" this
matter will be counted for purposes of determining whether sufficient
affirmative votes have been cast. An abstention from voting on a matter by a
stockholder present in person or represented by proxy at the meeting has the
same legal effect as a vote "against" the matter even though the stockholder or
interested parties analyzing the results of the voting may interpret such a vote
differently.
11
<PAGE>
MANNER IN WHICH THE PROXIES WILL BE VOTED
The Company proposes to vote management proxies and all unmarked proxies for
the election of each of the two nominees to the Board, each to hold office
during his three year term until his successor is elected and has qualified. In
the event that any nominee is not available to serve as a director at the time
of election, which the Company has no reason to anticipate, proxies may be voted
for such substitute nominee as the Company may propose.
The Company further proposes to vote management proxies and all unmarked
proxies for the selection of KPMG Peat Marwick LLP, as auditors for the ensuing
fiscal year. All members of the Board of Directors intend to vote in favor of
this proposal.
The Board knows of no other matter to be presented at the meeting. However,
if any other matter properly comes before the meeting, the persons named in the
proxy form enclosed will vote in accordance with their judgment upon such
matters. Stockholders who do not expect to attend in person are urged to execute
and return the enclosed form of proxy. Moreover, it is important that the
proxies be returned promptly.
PROPOSALS OF STOCKHOLDERS
Proposals of stockholders to be presented at the Company's 1997 Annual
Meeting of Stockholders must be received by the Company's Secretary at the
Company's Executive Office no later than 5:00 p.m., December 15, 1996, for
inclusion in next year's Proxy Statement.
By Order of the Board of Directors
John A. Hageman, Secretary
Miami, Florida
May 6, 1996
12
<PAGE>
PHYSICIAN CORPORATION
OF AMERICA
5835 BLUE LAGOON DRIVE
---------------------------------------------------------
P R O X Y
MIAMI, FLORIDA 33126
This Proxy is Solicited on Behalf of the Board of Directors
The undersigned hereby appoints E. Stanley Kardatzke, M.D. and Peter E.
Kilissanly as Proxies, each with the power to appoint his substitute, and hereby
authorizes them to represent and to vote, as designated below, all shares of
common stock of Physician Corporation of America, as held of record by the
undersigned on May 6, 1996, at the Annual Meeting of Stockholders to be held on
June 28, 1996, or any adjournment thereof.
<TABLE>
<S> <C> <C> <C> <C>
1. ELECTION OF DIRECTORS - FOR all nominees listed below (except - WITHHOLD AUTHORITY to vote for all
as marked to the contrary below) nominees listed below
</TABLE>
E. Stanley Kardatzke, M.D., George J. Farha, M.D.
(INSTRUCTION: To withhold authority to vote for any individual nominee, write
that nominee's name on the space provided below.)
- - --------------------------------------------------------------------------------
2. PROPOSAL to elect KPMG Peat Marwick LLP as the independent certified public
accountants of the corporation.
- FOR - AGAINST - ABSTAIN
(OVER FOR MORE QUESTIONS)
<PAGE>
3. IN THEIR DISCRETION, THE PROXIES ARE AUTHORIZED TO VOTE UPON SUCH OTHER
BUSINESS AS MAY PROPERLY COME BEFORE THE MEETING.
- - --------------------------------------------------------------------------------
The proxy when properly executed will be voted in the manner directed
herein by the undersigned stockholder. If no direction is made, this proxy will
be voted for Proposals 1 and 2.
Please sign exactly as name appears below. When shares are held by
joint tenants, either may sign. When signing as attorney, executor,
administrator, trustee or guardian, please give your full title.
IF A CORPORATION, PLEASE SIGN
IN FULL CORPORATE NAME BY
PRESIDENT OR OTHER AUTHORIZED
OFFICERS. IF A PARTNERSHIP,
PLEASE SIGN IN PARTNERSHIP NAME
BY AUTHORIZED PERSON.
PLACE LABEL HERE
Dated: ___________ , 1996
____________________________
Signature
____________________________
Signature, if held jointly
Please mark, sign, date and return this proxy
promptly by using the enclosed envelope.
